Sign inJoin waitlistJoin the waitlist

ZR

Zachary Reichert

Co-Director, Michigan Legacy Tissue Program · University of Michigan

Credentials: · · · ·

History

Michigan Legacy Tissue Program · University of Michigan
Present
University of Michigan
Present

Medical Oncology
2013–2015
Internal Medicine
University of Michigan
2010–2013
Johns Hopkins Univ Sch of Med
2006–2010

Research

CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors
JCO Precision Oncology · 2020 · 190 citations
Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study
Annals of Oncology · 2023 · First of 11 authors · 163 citations
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
New England Journal of Medicine · 2025 · 134 citations

Todd Morgan
21 papers
Joshi Alumkal
15 papers
Rohit Mehra
15 papers · 5 as a fellow
Daniel Spratt
14 papers
Samuel Kaffenberger
11 papers
AA
Ajjai Alva
10 papers
MC
Megan Caram
10 papers
UV
Ulka Vaishampayan
9 papers
Jeffrey Montgomery
8 papers
PP
Phillip Palmbos
8 papers
Rana McKay
8 papers · 5 as a resident
Aaron Udager
7 papers · 1 as a resident

Clinical trials

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Principal investigator · Recruiting · Phase 1, Phase 2
University of Michigan Rogel Cancer Center
2026–2030
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
Principal investigator · Active not recruiting · Phase 2
University of Michigan Rogel Cancer Center
2021–2027
Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)
Principal investigator · Active not recruiting · Phase 2
University of Michigan Rogel Cancer Center
2019–2028
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
Principal investigator · Completed · Phase 2
University of Michigan Rogel Cancer Center
2018–2023